Scynexis Inc (SCYX)

$1.44 0.04 (2.86%)

16:00 EDT SCYX Stock Quote Delayed 30 Minutes

SCYX Stock Earnings: SCYNEXIS Misses EPS, Beats Revenue for Q4 2023

By InvestorPlace Earnings Mar 28, 2024

SCYX stock results show that SCYNEXIS missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023.

Want to Get Rich? 3 Game-Changing Penny Stocks to Buy Right Now

Why Is Scynexis (SCYX) Stock Up 69% Today?

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

More Articles

Volume:

Previous Close -

Market Cap 53.53M

PE Ratio 0.82

EPS 1.75

Volume (Avg. Vol.) 130,980

Day's Range $1.39 - $1.47

52-Week Range $1.35 - $3.87

Dividend & Yield N/A (N/A)

SCYX Stock Predictions, Articles, and Scynexis Inc News

From InvestorPlace
From the Web

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

By William White, InvestorPlace Writer Apr 22, 2022

Traders ready for another busy day of investing will want to know all about the biggest pre-market stock movers for Friday!

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

By William White, InvestorPlace Writer Jun 2, 2021

Good morning! Let's get ready for another busy day of trading with a look at the biggest pre-market stock movers for Wednesday.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

By William White, InvestorPlace Writer Jun 1, 2021

Welcome back from the holiday weekend and let's get right into it with a look at the biggest pre-market stock movers for Tuesday.

5 Healthcare Stocks That Are Down, But Not Out!

By Josh Enomoto, InvestorPlace Contributor Aug 29, 2018

Tough headwinds have impacted several healthcare stocks, presenting opportunities for risk-tolerant speculators.

Scynexis stock falls as GSK amends deal for Brexafemme

From Seeking Alpha Jan 3, 2024

Scynexis (SCYX) stock dropped 9% after its license agreement for antifungal drug Brexafemme was amended by GSK (GSK) due to a recent product recall. Read more here.

SCYNEXIS files to sell 32.5M shares (NASDAQ:SCYX)

From Seeking Alpha Nov 13, 2023

SCYNCIS files to sell 32.5M shares of common stock, but the prospectus is not an offer to sell securities.

Scynexis hit by FDA clinical hold on antifungal trials (NASDAQ:SCYX)

From Seeking Alpha Oct 2, 2023

Scynexis faces setback as FDA imposes clinical hold on its anti-fungal therapy trials following product recall and voluntary hold. Read more here.

Scynexis wins $25M milestone from GSK over antifungal agent (NASDAQ:SCYX)

From Seeking Alpha Jun 21, 2023

Scynexis (SCYX) said Wednesday it earned a $25M performance-based milestone payment from GSK (GSK) over its studies into antifungal agent ibrexafungerp. Read more here.

SCYNEXIS stock jumps on licensing anti-fungal for GSK (NASDAQ:SCYX)

From Seeking Alpha Mar 30, 2023

GSK (GSK) and New Jersey-based biotech SCYNEXIS (SCYX) announced an exclusive license agreement on Thursday for Brexafemme (ibrexafungerp tablets), an FDA-approved treatment for...

Maxim Group Remains a Buy on SCYNEXIS (SCYX)

From TipRanks Dec 2, 2022

Maxim Group analyst Jason McCarthy maintained a Buy rating on SCYNEXIS (SCYX – Research Report) yesterday and set a price target of $7.00. The comp...

ADVERTISEMENT